Eric M. Friedman

Eric Friedman guides clients through all stages of product liability litigation, particularly working with expert witnesses to present the science behind clients' products. By leaning on his pre-law history as a biochemist, he is able to identify key arguments for and against clients and craft winning strategies for both motion practice and trial.

View the full bio for Eric M. Friedman at the Faegre Drinker website.

Articles by Eric M. Friedman:


Expert’s Results-Driven Methodology Leads to Exclusion and Summary Judgment in Paraquat MDL

Share

An expert witness is not supposed to pick a desired result and then reverse engineer inputs and methods that reach that result.  As the Ninth Circuit observed 30 years ago, “[c]oming to a firm conclusion first and then doing research to support it is the antithesis of [the scientific] method.”  Claar v. Burlington Northern R.R. Co., 29 F.3d 499, 502-03 (9th Cir. 1994).  A recent opinion from the Southern District of Illinois offers a fine example of an expert with a results-driven approach and a court that called him out on it.

In re Paraquat Products Liability Litigation, 2024 WL 1659687 (S.D. Ill. Apr. 17, 2024), arises from a multidistrict litigation (“MDL”) in which the plaintiffs claim to have developed Parkinson’s disease as a result of exposure to an herbicide, paraquat.  Four plaintiffs whose cases had been chosen for the MDL’s first trials offered a statistician (the parties disputed whether he also qualified as an epidemiologist) as their sole expert to establish general causation.  He had a difficult task, as no peer-reviewed literature established a link between paraquat exposure and Parkinson’s disease.  Indeed, when the court asked the plaintiffs to identify such literature, the plaintiffs could cite only a single opinion article.  That article had been shared with another of the plaintiffs’ experts before it was published, leading the court to conclude in deciding a prior discovery dispute that there was reason to investigate “whether counsel for the MDL plaintiffs, their experts, or other third parties may have influenced the contents of the article for the benefit of one side in the MDL.”  2023 WL 8372819 (S.D. Ill. Dec. 4, 2023).

Continue reading “Expert’s Results-Driven Methodology Leads to Exclusion and Summary Judgment in Paraquat MDL”

Missing the Mark: Summary Judgment Granted Where Plaintiff’s Experts Opine on Defect but Fail to Support Causation

Share

Product liability claims require proof of causation.  To be sure, they also require proof of some defect in the product and/or its accompanying warnings and product literature.  But defect and causation are separate elements of a prima facie claim, and both must be established – usually, through expert testimony.  As we have discussed on multiple occasions (for example, here and here), a plaintiff’s failure to offer admissible expert testimony on each element can lead to summary judgment.  A recent decision from the Eastern District of Pennsylvania offers yet another illustration.

In Slatowski v. Sig Sauer, Inc., 2024 WL 1078198 (E.D. Pa. Mar. 12, 2024), the plaintiff was an Immigration and Customs Enforcement (“ICE”) officer who was injured when his pistol fired unintentionally during a marksmanship training exercise.  He sued the gun manufacturer, alleging that a design defect in the gun’s integral safety feature – specifically, the lack of a tabbed trigger – caused the firearm to discharge unintentionally. The plaintiff proffered two experts in support of the claim:  a gunsmith and a certified firearms instructor and range safety officer with a Ph.D. in ergonomics.  The defendant moved to exclude both experts’ opinions and also moved for summary judgment, arguing that the plaintiff had no admissible expert testimony to establish causation.

Continue reading “Missing the Mark: Summary Judgment Granted Where Plaintiff’s Experts Opine on Defect but Fail to Support Causation”

California Appellate Court Upholds Federal Preemption of Negligent Undertaking Claim Under the Medical Device Amendments of 1976

Share

Federal preemption can be a very powerful defense.  For example, claims concerning Class III medical devices requiring pre-market approval are generally preempted by the Medical Device Amendments of 1976, 21 U.S.C. § 360c, et seq. (“MDA”).  In Regwan v. Abbott Laboratories, Case No. B319606, 2023 WL 8818748 (Cal. App. 2d Dec. 21, 2023), the California Court of Appeal relied on that principle in holding preempted a negligent failure to warn claim premised on a sales representative’s intraoperative communications and presented as a “negligent undertaking” claim.  This holding continues a California trend that federal law may preempt negligence-based claims regarding Class III PMA medical devices even if they are not presented as traditional design defect or failure to warn claims.

In Regwan, the plaintiff alleged she suffered serious injuries following implantation of a MitraClip that the defendant manufactured.  During the procedure, the saline bag ran dry, causing the plaintiff to allegedly suffer an air embolism and brain injuries.  The plaintiff asserted negligence and products liability causes of action against the defendant after discovering a defendant representative attended the surgery and was allegedly “responsible for the flow of saline.”  The defendant demurred, arguing federal law preempted the plaintiff’s products liability claims.

Continue reading “California Appellate Court Upholds Federal Preemption of Negligent Undertaking Claim Under the Medical Device Amendments of 1976”

Old Habits Die Hard: First Circuit Cites Newly Amended Language of FRE 702 But Follows Abrogated Precedent Instead

Share

The longer and more frequently a principle is repeated by the courts, the more difficult it can be for courts to acknowledge change.  As illustrated by the First Circuit’s opinion in Rodriguez v. Hospital San Cristobal, Inc., 91 F.4th 59 (1st Cir. 2024) – the first reported appellate decision to cite the language of the newly-amended Federal Rule of Evidence 702 since it took effect in December 2023 – even a change to the Federal Rules of Evidence themselves might not be enough for a court to stop citing outdated but familiar precedents.

Some background is in order.  In 1993, Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) ushered in a new paradigm for evaluating the admissibility of expert opinion evidence.  Courts seized on Daubert’s comment that a court’s “focus, of course, must be solely on [an expert’s] principles and methodology, not on the conclusions that they generate.”  But just four years after Daubert was decided, the Supreme Court rejected an argument that a lower court had erred by evaluating an expert’s conclusions.  Because “conclusions and methodology are not entirely distinct from one another,” the lower court had not abused its discretion in evaluating whether the expert’s opinion was warranted by the data on which it was based.  General Electric Co. v. Joiner, 522 U.S. 136 (1997).

Continue reading “Old Habits Die Hard: First Circuit Cites Newly Amended Language of FRE 702 But Follows Abrogated Precedent Instead”

Amended FRE 702 Arrives in MDL Practice: S.D.N.Y. Excludes Plaintiffs’ Experts in Acetaminophen MDL

Share

The Committee Notes to the newly implemented amendments to Federal Rule of Evidence 702 make clear that the “[j]udicial gatekeeping” of expert evidence is “essential.”  Federal courts in New York have played an important role in pioneering and developing this concept.  Indeed, the idea of courts as gatekeepers in the expert context finds its roots in the Eastern District of New York, with the late Chief Judge Weinstein coining the term in a 1985 opinion in In re Agent Orange Product Liability Litigation.  Three decades later, the Southern District of New York offered one of the most thorough illustrations of careful judicial gatekeeping in In re Mirena IUS Levonorgestrel-Related Prod. Liab. Litig. (No. II).  Now, New York can also call itself home to the first MDL-wide decision to exclude experts under Rule 702’s new formulation.

Continue reading “Amended FRE 702 Arrives in MDL Practice: S.D.N.Y. Excludes Plaintiffs’ Experts in Acetaminophen MDL”

Something to Celebrate: A Brief Guide to the FRE 702 Amendments

Share

Fun fact:  There are 23 holidays that can be celebrated today, December 1st.  Some, like Rosa Parks Day and World AIDS Day, are solemn and serious.  Others are silly and fun, like National Peppermint Bark Day and National Christmas Lights Day.  And then there are those that are downright strange, like Bifocals at the Monitor Liberation Day.  (No, we didn’t make that up.)  But for those of us who practice in the federal courts, we can add one more celebration to this esteemed list.

Today, the long-anticipated amendments to Federal Rule of Evidence 702, governing admissibility of expert opinion evidence, finally take formal effect.  The amendments were unanimously approved by the Advisory Committee over two and a half years ago.  Courts have been citing the proposed amendments since shortly after they were first approved.  On the surface, the amendments to the text of Rule 702 itself may appear relatively modest.  Indeed, at least one court has observed that the new language “clearly echoes the existing law on the issue.”  Sardis v. Overhead Door Corp., 10 F.4th 268 (4th Cir. 2021).  But there is more to these new amendments than initially meets the eye.  In order to understand and effectively use the amendments, parties and litigators must understand and use the history and the Committee Note explaining the amendments.

Continue reading “Something to Celebrate: A Brief Guide to the FRE 702 Amendments”